Adverse outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors

Heart. 2021 Oct;107(20):1680. doi: 10.1136/heartjnl-2021-319414. Epub 2021 Jun 30.

Authors

Alexa Papaila¹, Mark Godding², Michael Liu²

Affiliations

¹ Department of Internal Medicine, Brown University, Providence, Rhode Island, USA apapaila@lifespan.org.
² Department of Internal Medicine, Brown University, Providence, Rhode Island, USA.

PMID: 34193465
DOI: 10.1136/heartjnl-2021-319414

No abstract available

Keywords: drug monitoring; heart failure; research design.

Publication types

Letter
Comment

MeSH terms

Chronic Disease
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Protein Kinase Inhibitors / adverse effects

Substances

Protein Kinase Inhibitors